Premium
Oral itraconazole therapy for pityriasis versicolor
Author(s) -
Georgiou S.,
Monastirli A.,
Pasmatzi E.,
Zografakis C.,
Tsambaos D.
Publication year - 1997
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1997.tb00479.x
Subject(s) - pityriasis , medicine , itraconazole , nausea , dermatology , vomiting , gastroenterology , surgery , antifungal
The therapeutic efficacy and safely of oral itraconazole (200 mg/day for 7 days) was assessed in an open trial in 50 patients with pityriasis versicolor. At the end of the I‐week therapy complete remission and marked improvement were observed in 44% and 48% of the treated patients, respectively: 8% of the patients who showed no response were treated for 1 more week and also revealed a complete remission by the end of she 3‐week follow‐up (50/50). Headache and/or nausea occurred in 6% of the patients, whereas, the haematological and biochemical investigations revealed no abnormalities. The results of the present study clearly indicate that oral itraconazole is a highly efficacious and safe treatment for pityriasis versicolor.